🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System

RecruitingNAAges 18 Years - anyAllBeijing Tiantan Hospital
NCT06783049 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value. Participants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group). At one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients diagnosed with acute ischemic stroke or transient ischemic attack. 3. Time from onset to enrollment ≤ 14 days. 4. Presence of at least one modifiable risk factor (hypertension, diabetes). 5. Ability to independently use a smartphone to complete system tasks upon discharge, or with the assistance of family members. 6. Signed informed consent by the patient or their family members. Exclusion Criteria: 1. Patients already enrolled in other stroke-related healthcare quality improvement projects or clinical trials. 2. Patients or family members who refuse to sign the informed consent form. 3. Pregnant or breastfeeding women.
💊

What it tests

  • Cerebrovascular Disease Secondary Prevention Smart Management System
📍

Where

3 sites
Beijing Tsinghua Changgung Hospital
Beijing, China
The First Affiliated Hospital of Shihezi University
Shihezi, China
Beijing Tiantan Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy